
    
      The aim of this study is to assess bioequivalence between a single dose from the test
      product, Sulfadoxine/ Pyrimethamine tablets (500 mg sulfadoxine / 25 mg pyrimethamine),
      manufactured by Ms. Emzor Pharmaceuticals Industries Ltd, Nigeria versus the reference
      product G-COSPEÂ® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) manufactured by Guilin
      Pharmaceutical Co. Ltd, China under fasting conditions and to monitor the safety of the
      subjects.
    
  